- Home
- SSSS vs NTHI Comparison
SSSS vs NTHI Comparison
Compare SSSS & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- NTHI
- Stock Information
- Founded
- SSSS 2010
- NTHI 2008
- Country
- SSSS United States
- NTHI United States
- Employees
- SSSS N/A
- NTHI N/A
- Industry
- SSSS Finance: Consumer Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- NTHI Health Care
- Exchange
- SSSS Nasdaq
- NTHI Nasdaq
- Market Cap
- SSSS 138.2M
- NTHI 142.5M
- IPO Year
- SSSS N/A
- NTHI N/A
- Fundamental
- Price
- SSSS $8.21
- NTHI $3.40
- Analyst Decision
- SSSS Strong Buy
- NTHI
- Analyst Count
- SSSS 3
- NTHI 0
- Target Price
- SSSS $8.67
- NTHI N/A
- AVG Volume (30 Days)
- SSSS 369.3K
- NTHI 26.9K
- Earning Date
- SSSS 08-06-2025
- NTHI 01-01-0001
- Dividend Yield
- SSSS N/A
- NTHI N/A
- EPS Growth
- SSSS N/A
- NTHI N/A
- EPS
- SSSS N/A
- NTHI N/A
- Revenue
- SSSS $3,644,430.00
- NTHI $79,990.00
- Revenue This Year
- SSSS $5,400.03
- NTHI N/A
- Revenue Next Year
- SSSS N/A
- NTHI N/A
- P/E Ratio
- SSSS N/A
- NTHI N/A
- Revenue Growth
- SSSS N/A
- NTHI 13.52
- 52 Week Low
- SSSS $3.52
- NTHI $3.24
- 52 Week High
- SSSS $8.77
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SSSS 77.74
- NTHI N/A
- Support Level
- SSSS $7.26
- NTHI N/A
- Resistance Level
- SSSS $8.77
- NTHI N/A
- Average True Range (ATR)
- SSSS 0.30
- NTHI 0.00
- MACD
- SSSS 0.03
- NTHI 0.00
- Stochastic Oscillator
- SSSS 77.11
- NTHI 0.00
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").